Closely-held Indalo Therapeutics appointed Michael Heffernan as chair of its board of directors.
“Indalo’s unique approach to treating fibrosis, combined with a highly experienced team and world-class financial backers, is poised to make a meaningful impact in serious fibrotic diseases,” Mr. Heffernan said in a statement.
“I look forward to working with the Indalo team as the company advances its compelling lead program and continues to expand its pipeline of integrin antagonists,” he added.
Mr. Heffernan founded and was most recently CEO of Collegium Pharmaceutical (NASDAQ:COLL). He also co-founded and is actively managing Avenge Bio, an immuno-oncology company. He was previously CEO of Onset Dermatologics; CEO of Clinical Studies, which he co-founded; and CEO and chairman PhyMatrix.
